|
Category
|
2014 n (%)
|
2015 n (%)
|
2016 n (%)
|
2017 n (%)
|
2018 n (%)
|
2019 n (%)
|
Total n (%)
|
χ2
|
P
|
|---|
|
All TB cases
|
|
Any drug-resistance
|
95 (42.6)
|
85 (49.7)
|
60 (56.1)
|
96 (50.5)
|
127 (38.4)
|
195 (42.2)
|
658 (44.3)
|
16.820
|
0.005
|
|
INH
|
71 (31.8)
|
67 (39.2)
|
42 (39.3)
|
68 (35.8)
|
85 (25.7)
|
132 (28.6)
|
465 (31.3)
|
16.349
|
0.006
|
|
RIF
|
60 (26.9)
|
63 (36.8)
|
48 (44.9)
|
68 (35.8)
|
86 (26.0)
|
136 (29.4)
|
461 (31.1)
|
20.521
|
0.001
|
|
EMB
|
23 (10.3)
|
12 (7.0)
|
20 (18.7)
|
26 (13.7)
|
26 (7.9)
|
41 (8.9)
|
148 (10.0)
|
15.941
|
0.007
|
|
STR
|
48 (21.5)
|
39 (22.8)
|
24 (22.4)
|
50 (26.3)
|
56 (16.9)
|
98 (21.2)
|
315 (21.2)
|
6.977
|
0.222
|
|
MDR
|
54 (24.2)
|
50 (29.2)
|
38 (35.5)
|
53 (27.9)
|
63 (19.0)
|
111 (24.0)
|
369 (24.9)
|
15.430
|
0.009
|
|
Any second-line drug resistance
|
42 (18.8)
|
43 (25.1)
|
34 (31.8)
|
46 (24.2)
|
47 (14.2)
|
96 (20.8)
|
308 (20.8)
|
20.435
|
0.001
|
|
CPM
|
2 (0.9)
|
3 (1.8)
|
3 (2.8)
|
7 (3.7)
|
6 (1.8)
|
21 (4.5)
|
42 (2.8)
|
10.443
|
0.064
|
|
KAR
|
6 (2.7)
|
5 (2.9)
|
7 (6.5)
|
13 (6.8)
|
6 (1.8)
|
14 (3.0)
|
51 (3.4)
|
13.119
|
0.022
|
|
OFX
|
38 (17.0)
|
41 (24.0)
|
33 (30.8)
|
42 (22.1)
|
43 (13.0)
|
76 (16.5)
|
273 (18.4)
|
24.208
|
< 0.001
|
|
PTO
|
1 (0.4)
|
1 (0.6)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
18 (3.9)
|
20 (1.3)
|
34.796
|
< 0.001
|
|
XDR
|
4 (1.8)
|
3 (1.8)
|
5 (4.7)
|
10 (5.3)
|
4 (1.2)
|
7 (1.5)
|
33 (2.2)
|
11.580
|
0.041
|
|
New cases
|
|
Any drug-resistance
|
35 (28.0)
|
22 (25.0)
|
13 (33.3)
|
29 (30.9)
|
47 (24.0)
|
67 (23.7)
|
213 (25.8)
|
3.759
|
0.585
|
|
INH
|
22 (17.6)
|
14 (15.9)
|
6 (15.4)
|
17 (18.1)
|
27 (13.8)
|
36 (12.7)
|
122 (14.8)
|
2.813
|
0.729
|
|
RIF
|
15 (12.0)
|
8 (9.1)
|
7 (17.9)
|
13 (13.8)
|
23 (11.7)
|
28 (9.9)
|
94 (11.4)
|
3.181
|
0.672
|
|
EMB
|
6 (4.8)
|
2 (2.3)
|
1 (2.6)
|
4 (4.3)
|
6 (3.1)
|
11 (3.9)
|
30 (3.6)
|
1.462
|
0.917
|
|
STR
|
17 (13.6)
|
9 (10.2)
|
6 (15.4)
|
13 (13.8)
|
25 (12.8)
|
31 (11.0)
|
101 (12.2)
|
1.604
|
0.901
|
|
MDR
|
14 (11.2)
|
4 (4.5)
|
5 (12.8)
|
8 (8.5)
|
15 (7.7)
|
25 (8.8)
|
71 (8.6)
|
4.210
|
0.520
|
|
Any second-line drug resistance
|
13 (10.4)
|
7 (8.0)
|
7 (17.9)
|
11 (11.7)
|
12 (6.1)
|
26 (9.2)
|
76 (9.2)
|
6.397
|
0.270
|
|
CPM
|
1 (0.8)
|
1 (1.1)
|
0 (0.0)
|
3 (3.2)
|
3 (1.5)
|
7 (2.5)
|
15 (1.8)
|
4.133
|
0.530
|
|
KAR
|
2 (1.6)
|
1 (1.1)
|
0 (0.0)
|
4 (4.3)
|
1 (0.5)
|
6 (2.1)
|
14 (1.7)
|
6.696
|
0.244
|
|
OFX
|
10 (8.0)
|
7 (8.0)
|
7 (17.9)
|
8 (8.5)
|
10 (5.1)
|
17 (6.0)
|
59 (7.2)
|
7.388
|
0.193
|
|
PTO
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
2 (0.7)
|
2 (0.2)
|
4.289
|
0.509
|
|
XDR
|
0 (0.0)
|
1 (1.1)
|
0 (0.0)
|
1 (1.1)
|
0 (0.0)
|
1 (0.4)
|
3 (0.4)
|
4.383
|
0.496
|
|
Retreatment cases
|
|
Any drug-resistance
|
60 (61.2)
|
63 (75.9)
|
47 (69.1)
|
67 (69.8)
|
80 (59.3)
|
128 (71.5)
|
445 (67.5)
|
10.236
|
0.069
|
|
INH
|
49 (50.0)
|
53 (63.9)
|
36 (52.9)
|
51 (53.1)
|
58 (43.0)
|
96 (53.6)
|
343 (52.0)
|
9.512
|
0.090
|
|
RIF
|
45 (45.9)
|
55 (66.3)
|
41 (60.3)
|
55 (57.3)
|
63 (46.7)
|
108 (60.3)
|
367 (55.7)
|
14.257
|
0.014
|
|
EMB
|
17 (17.3)
|
10 (12.0)
|
19 (27.9)
|
22 (22.9)
|
20 (14.8)
|
30 (16.8)
|
118 (17.9)
|
9.294
|
0.098
|
|
STR
|
31 (31.6)
|
30 (36.1)
|
18 (26.5)
|
37 (38.5)
|
31 (23.0)
|
67 (37.4)
|
214 (32.5)
|
10.845
|
0.055
|
|
MDR
|
40 (40.8)
|
46 (55.4)
|
33 (48.5)
|
45 (46.9)
|
48 (35.6)
|
86 (48.0)
|
298 (45.2)
|
10.328
|
0.066
|
|
Any second-line drug resistance
|
29 (29.6)
|
36 (43.4)
|
27 (39.7)
|
35 (36.5)
|
35 (25.9)
|
70 (39.1)
|
232 (35.2)
|
10.741
|
0.057
|
|
CPM
|
1 (1.0)
|
2 (2.4)
|
3 (4.4)
|
4 (4.2)
|
3 (2.2)
|
14 (7.8)
|
27 (4.1)
|
10.541
|
0.061
|
|
KAR
|
4 (4.1)
|
4 (4.8)
|
7 (10.3)
|
9 (9.4)
|
5 (3.7)
|
8 (4.5)
|
37 (5.6)
|
6.544
|
0.257
|
|
OFX
|
28 (28.6)
|
34 (41.0)
|
26 (38.2)
|
34 (35.4)
|
33 (24.4)
|
59 (33.0)
|
214 (32.5)
|
8.806
|
0.117
|
|
PTO
|
1 (1.0)
|
1 (1.2)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
16 (8.9)
|
18 (2.7)
|
35.332
|
< 0.001
|
|
XDR
|
4 (4.1)
|
2 (2.4)
|
5 (7.4)
|
9 (9.4)
|
4 (3.0)
|
6 (3.4)
|
30 (4.6)
|
7.670
|
0.175
|
- Abbreviation: INH, isoniazid; RIF, rifampin; EMB, ethambutol; STR, streptomycin; first-line drug resistance, including isoniazid, rifampin ethambutol and streptomycin; MDR, multi-drug resistant; CPM, capreomycin; KAR, kanamycin; OFX, ofloxacin; PTO, protionamide; XDR, extensively drug-resistant
